Personalis
Personalis, Inc. (NASDAQ PSNL) is a clinical genomics and cancer diagnostics company based in Fremont, California. It develops advanced tumor and immune profiling tests built on next-generation sequencing, including its NeXT Personal ultra-sensitive tumor-informed molecular residual disease (MRD) and recurrence-monitoring assay and the ImmunoID NeXT whole-exome and transcriptome platform used for translational cancer research, biopharma partnerships, and population sequencing programs. Personalis operates as a diagnostics laboratory and research-services provider; its offerings are delivered as clinical tests, sequencing services, and analytical reports rather than as a public developer API. No public developer portal, API reference, or SDK is published as of this enrichment pass.
Personalis is profiled on the APIs.io network. Tagged areas include Company, Genomics, Oncology, Diagnostics, and Sequencing.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 1
The organization behind the API